Ibrutinib (PCI-32765,Imbruvica) is an effective and highly selective inhibitor of Brutons tyrosine kinase (Btk) with an IC50 of 0.5 nM in cell-free tests. BRK and HCK are moderately effective, but have weak effects on EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib can be used as a Btk ligand to synthesize a range of proTACs, including P13I.

 

Brand: BCM

 

Target: Tyrosine Kinases: Ligands for Target Protein for PROTAC; Src; BTK

 

Signaling Pathways: Angiogenesis; PROTAC; Tyrosine Kinase/Adaptors

 

Melting Point: 153-158°C

 

Solubility: Soluble in DMSO; soluble in Ethanol (warmed with 50ºC water bath). Insoluble in Water.

 

GHS: GHS07, GHS06

 

Isomeric SMILES: C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N  

 

InChIKey: XYFPWWZEPKGCCK-GOSISDBHSA-N  

 

InChI: InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

 

Attribute
[CAS No.]	936563-96-1
[EINECS]	805-642-2
[Formula]	C25H24N6O2
[Molecular]	440.507
[Chem Name]	1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
[Storage]	Keep in dark place. Inert atmosphere, 2-8°C
[Synonym]	Ibrutinib; PCI-32765; PCI32765; Imbruvica
[MDL No.]	MFCD20261150
[Form]	White or off-white solid

Goods Tag